No Detail Found!

Expert Opinion: use of Sodium Glucose Co-transporter Type-2 Inhibitors in South Asian Population -the Pakistan Perspective.

Author(s)
Syed Abbas Raza Shaukat Khanum Cancer Hospital and Research Center. Johar Town,Lahore, Punjab.,Pakistan
A. H. Aamir Hayatabad Medical Complex Peshawar.,Pakistan
Ali Jawa Wilshire Cardiovascular and Endocrine Center of Excellence WILCARE Lahore,Pakistan
Faisal Masood Qureshi Al Khaliq Hospital, Multan Pakistan
Ibrar Ahmad Lady Reading Hospital Peshawar,Pakistan
Khalid Mahmud Khan Allama Iqbal Medical College Lahore,Pakistan
Khursheed Khan Allama Iqbal Medical College Lahore,Pakistan
Nauman Naseer Akhtar Saeed Medical College,Lahore,Pakistan
Najmul Islam AKUH Karachi,Pakistan
Osama Ishtiaq Shifa International Hospital Islamabad,Pakistan
Saeed Ahmed Mahar National Institute of Cardiovascular Diseases Karachi,Pakistan
Abstract
Sodium-glucose co-transporter type 2 inhibitors (SGLT 2i)are increasingly being used in the management of type 2 diabetes mellitus (T2DM). With the novel insulinindependent glycosuric action, these agents help to attain glycaemic goals by lowering HbA1c and fasting blood glucose. In addition, these agents improve metabolic control in diabetes and ameliorate comorbidities like obesity and hypertension. Beneficial effects on cardiovascular outcomes have been a key attraction for physicians. These agents are used alone or in combination with oral antidiabetic agents and insulin to attain glycaemic and metabolic targets. A major disadvantage with these agents is the increased risk for genital and urinary infections. When used in appropriate settings, there is no additional increased risk of hypoglycaemia or volume depletion with these agents. Available evidence suggests good efficacy and safety of these agents in diabetes management. The easy and convenient oncedaily dosing should be customized according to patient needs and glycaemic profiles.
Publication Details
Page(s) 555-563
DOI DOI not available
Published Journal: Journal of Pakistan Medical Association, Volume: 69, Issue: 4, Year: 2019

Request the full text from PASTIC

Keywords
canagliflozin empagliflozin, dapagliflozin, SGLT-2, ertugliflozin
0

Citations

0

Downloads

62

Views